FDA — Fidia SpA Income Statement
0.000.00%
Last trade - 00:00
- €3.94m
- €7.51m
- €24.37m
- 29
- 69
- 15
- 27
2018 December 31st | 2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 57.7 | 45.8 | 21.2 | 23.8 | 24.4 |
Cost of Revenue | |||||
Gross Profit | 33.5 | 26.9 | 13.7 | 15.5 | 14.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 58.4 | 49.3 | 27 | 25.4 | 29.3 |
Operating Profit | -0.695 | -3.47 | -5.74 | -1.58 | -4.92 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.25 | -4.2 | -6.04 | -3.26 | 5.55 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.55 | -4.48 | -5.95 | -3.5 | 5.75 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -1.31 | -4.12 | -5.71 | -3.2 | 5.97 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.31 | -4.12 | -5.71 | -3.2 | 5.97 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.224 | -0.81 | -1.07 | -0.616 | 0.907 |
Dividends per Share |